

REDX PHARMA LIMITED

("Redx" or the "Company")

Redx to present RXC008 Phase 1 Data at ECCO

Presentation will include Healthy Volunteer Data for Potential First-in-Class Gastrointestinal Restricted pan-ROCK inhibitor developed for treatment of intestinal fibrosis

Alderley Park, UK, 7 February 2025 [Redx Pharma](#) (JPJ:REDX), the clinical-stage, small molecule biotechnology company, will present on RXC008, a highly potent and selective gastrointestinal (GI) tract restricted pan-ROCK inhibitor at the 20th Congress of European Crohn's and Colitis Organisation Conference (ECCO), February 19-22, 2025, Berlin, Germany.

Rho-associated coiled kinase (ROCK), comprising ROCK 1 and ROCK 2 is a nodal target for antifibrotic therapies. Systemic treatment with pan-ROCK inhibitors leads to adverse hypotensive effects.^{1,2} RXC008, a highly potent and selective GI tract restricted pan-ROCK inhibitor was specifically designed to achieve antifibrotic effects in the GI tract without significant systemic exposure.

The Phase 1 study aimed to assess the safety, tolerability, local and systemic exposure of RXC008 in healthy participants as part of a clinical development program for intestinal fibrosis.

Crohn's disease affects 1.7m^{3,4} people globally and >70,000 new cases are diagnosed each year. More than 50%⁴ of patients with Crohn's disease can develop significant fibrosis and stricture formation within ten years after diagnosis; this fibrosis associated with Crohn's disease is known as fibrostenotic Crohn's disease. The current management of fibrotic strictures of the gastrointestinal tract is primarily surgical as no drugs are specifically approved for fibrosis, which can progress despite intervention with anti-inflammatory therapies.

Digital Oral Presentation Details:

Title: *RXC008, a first-in-class gastrointestinal restricted pan-ROCK inhibitor developed for treatment of intestinal fibrosis shows GI restriction and tolerability: Results from the phase 1 program in healthy participants.*

Presenter: *Dr Florian Rieder, M.D., Vice Chair, Co-Section Director Inflammatory Bowel Diseases, Director Cleveland Clinic Program for Global Translational Inflammatory Bowel Diseases, Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, USA*

Session: *Session 12: Clinical Trials and Diagnostics*

Day/Date: *Friday 21 February 2025*

Presentation Time: *17:35-18:35 EST*

Location: *Messe Berlin, City Cube, Messedamm 26, 14055 Berlin, Germany & Congress Center*

A copy of the abstract presentation deck will be made available on the Company website after the conference at: <https://www.redxpharma.com/scientific-publications>.

For further information, please contact:

Redx Pharma Limited

Erin Hamid, Interim Head of Communications
ir@redxpharma.com

T: +44 (0)1625 469 918

FTI Consulting

Simon Conway/ Ciara Martin

T: +44 (0)203 727 1000

About Redx Pharma Limited

Redx Pharma (JPJ: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company is currently progressing an industry leading ROCK inhibitor portfolio through the clinic, including zelasudil, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis and RXC008, a GI-targeted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease. Additionally, the Company has a Phase 2 precision oncology programme which it intends to partner for further development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.

-
1. Noma, K. et al: Physiological role of ROCKs in the cardiovascular system. *Am J Physiol Cell Physiol.* 2006 Mar;290(3):C661-8.2.
 2. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. *Heart Vessels.* 2010 Mar;25(2):144-9. doi: 10.1007/s00380-009-1176-8. Epub 2010 Mar 26. PMID: 20339976.
 3. Clarivate, Crohn's disease landscape & forecast p.g. 39, Published Sep 2022.
 4. Chan et al, 2018